Business
ProQR Announces First Quarter 2025 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --
About this update from Proqr Therapeutics N.v.
[{"type":"image","alt":"ProQR Therapeutics N.V.","displaySize":"","headline":null,"caption":"ProQR Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4HUbXKqR88bsVsQR5pPVmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3","width":150,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership","length":146,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":426,"olType":false},{"type":"text","content":"LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.","length":392,"tagName":"p"},{"type":"text","content":"“ProQR entered 2025 in a position of strength, with solid fundamentals, a well-capitalized balance sheet, and a clear focus on execution,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “We remain on track to submit the CTA for our lead RNA editing program, AX-0810 targeting NTCP for cholestatic diseases, in Q2 2025, with our first clinical data readout expected in Q4 – key milestones for our lead Axiomer pipeline program that we believe will drive significant value for stakeholders. I’m delighted that we further strengthened our leadership team with the recent appointments of Chief Financial Officer Dennis Hom and Chief Medical Officer Dr. ...